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Abstract
Introduction  and  aims:  The  chronic  use  of  nonsteroidal  anti-inﬂammatory  drugs  (NSAIDs)  can
cause complications  in  the  gastrointestinal  tract.  The  use  of  proton  pump  inhibitors  (PPIs)  is
recommended  in  high-risk  patients  to  prevent  them.
Objective:  The  aim  of  this  article  was  to  evaluate  the  gastroprotection  measures  taken  in
persons with  chronic  NSAID  use.
Materials  and  methods:  A  descriptive  cross-sectional  study  was  conducted.  The  clinical  records
were reviewed  of  patients  seen  as  outpatients  at  the  Rheumatology  Department  over  a  4-month
period, choosing  those  with  chronic  NSAID  use,  and  intentionally  looking  for  gastroprotection
measures according  to  the  recommendations  published  by  the  American  College  of  Gastroen-
terology.
Results: A  total  of  417  patients  (347  women;  mean  age:  48.12  ±  14.2  years)  were  included.
The most  frequent  diagnosis  was  rheumatoid  arthritis  (65%).  Nine  patients  (2.1%)  had  a  history
of peptic  ulcer,  48  (11.5%)  patients  were  65  years  of  age  or  older,  26  (6.2%)  patients  took
NSAIDs and  aspirin,  and  130  (31.2%)  took  NSAIDs  with  steroids.  Tests  for  Helicobacter  pylori
infection  were  done  in  just  53  cases,  and  there  were  positive  results  in  only  9  (16%).  Some
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risk  for  gastrointestinal  toxicity  was  established  in  211  cases  and  only  65  (30.8%)  received
gastroprotection.  In  contrast,  31  (15%)  patients  received  gastroprotection  when  there  was  no
indication  for  it.
Conclusion:  Prophylaxis  with  PPIs  in  chronic  NSAID  users  was  inadequately  employed.  It  was  not
prescribed  in  the  majority  of  patients  (69.2%)  and  it  was  used  with  no  justiﬁcation  in  others
(15%).
© 2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Published  by  Masson  Doyma  Me´xico  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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¿Qué  tanto  se  siguen  las  recomendaciones  de  las  guías  clínicas  sobre
gastroprotección?  Una  revisión  en  enfermos  que  consumen  antiinﬂamatorios  no
esteroideos
Resumen
Antecedentes:  El  uso  crónico  de  antiinﬂamatorios  no  esteroideos  (AINE)  puede  provocar  com-
plicaciones  en  el  tracto  gastrointestinal.  Para  prevenirlas,  se  recomienda  el  uso  de  inhibidores
de la  bomba  de  protones  (IBP)  en  los  enfermos  de  alto  riesgo.
Objetivo:  Evaluar  las  medidas  de  gastroprotección  en  personas  que  usan  AINE  en  forma  crónica.
Material y  métodos:  Estudio  descriptivo  y  transversal.  Se  revisaron  los  expedientes  clínicos  de
los enfermos  que  acudían  a  la  consulta  externa  de  reumatología  durante  4  meses  y  se  eligieron
a los  que  utilizaban  AINE  de  forma  crónica.  Se  buscaron  intencionadamente  las  medidas  de
gastroprotección  de  acuerdo  con  las  recomendaciones  publicadas  por  el  Colegio  Americano
de Gastroenterología.
Resultados:  Se  incluyó  a  417  pacientes  (347  mujeres;  edad  promedio=  48.12  ±  14.2  an˜os).  El
diagnóstico  más  frecuente  fue  artritis  reumatoide  (65%).  Nueve  pacientes  (2.1%)  tenían  his-
toria de  úlcera  péptica.  Cuarenta  y  ocho  (11.5%)  enfermos  tenían  65  an˜os  o  más.  Veintiséis
(6.2%) tomaban  AINE  y  aspirina,  y  130  (31.2%)  AINE  con  esteroides.  En  53  casos  (12.7%)  se
conocía el  estatus  de  infección  por  Helicobacter  pylori  que  fue  positivo  en  solo  9  (16%).  En
211 casos  se  estableció  algún  riesgo  para  toxicidad  gastrointestinal  y  solo  65  (30.8%)  recibía
gastroprotección.  En  cambio,  31  (15%)  lo  recibieron  sin  ninguna  indicación.
Conclusión:  La  proﬁlaxis  con  IBP  en  usuarios  crónicos  de  AINE  se  emplea  de  manera  inadecuada.
En su  mayoría  no  se  indica  (69.2%)  y  en  otras  se  utiliza  sin  justiﬁcación  (15%).
© 2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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onsteroidal  anti-inﬂammatory  drugs  (NSAIDs)  are  the  most
idely  prescribed  drugs  worldwide  and  their  use  has
ubstantially  decreased  the  morbidity  and  mortality  of  car-
iovascular  disease  and  improved  the  quality  of  life  in
ersons  that  suffer  from  chronic  pain.1 Low  doses  of  platelet
ntiaggregants  have  been  shown  to  be  efﬁcacious  in  pri-
ary  as  well  as  secondary  prevention  of  cardiovascular
vents  in  high-risk  persons,  mainly  those  of  advanced  age
nd  that  present  with  comorbidities.2,3 In  addition,  they
re  efﬁcacious  as  analgesics  and  anti-inﬂammatory  agents
nd  are  used  as  part  of  treatment  for  rheumatologic  dis-
ases,  post-trauma,  and  neoplasias.4 Unfortunately  their
hronic  use  can  cause  adverse  effect  in  the  digestive  tract
hat  vary  from  dyspeptic  symptoms  to  severe  complications
uch  as  bleeding  and  perforation.5,6 Thus  an  effort  has  been
ade  to  identify  the  risk  factors  associated  with  these
a
d
i
Tomplications  in  order  to  provide  preventive  measures. Sev-
ral  studies  have  shown  that  age  above  65  years,  a  previous
istory  of  peptic  ulcer  disease,  high  doses  of  NSAIDs,  con-
omitant  use  of  anticoagulants,  steroids  and/or  aspirin,
nd  H.  pylori  infection  are  determining  factors  of  NSAID
amage.7,8 Clinical  guidelines  have  described  various  strate-
ies  for  the  prevention  of  harmful  NSAID  effects.9,10 The
atest  ones  published  in  2009  by  the  American  College
f  Gastroenterology  suggest  gastroprotection  measures  in
ccordance  with  the  risk  for  gastrointestinal  involvement
lassiﬁed  as  low,  moderate,  and  high,  and  they  include  car-
iovascular  risk,  given  the  known  cardiotoxicity  of  NSAIDs
nd  aspirin.11 The  primary  prophylactic  measure  is  to  use
he  standard  dose  of  proton  pump  inhibitor  (PPI),  as  well
s  the  least  ulcerogenic  NSAID  and  the  lowest  effective
ose.12,13 But  despite  the  guidelines,  there  is  evidence  of
nadequate  use  of  the  primary  prophylactic  measures.14,15
here  are  no  studies  in  Mexico  on  gastroprotection  measures
tion  being  followed?  123
Table  1  General  characteristics  of  the  patients  using
NSAIDs (n  =  417).
Variable  Results  (%)
Sex
Women  347  (83.2)
Men 70  (16.8)
Age (years),  mean  ±  SD  48.12  ±  14.2,
(interval:
18-85)
Patients  >  65  years  of  age 48  (11.5)
Primary  diagnosis  (ﬁrst  5)
Rheumatoid  arthritis  272  (65.2)
Ankylosing  spondylitis  52  (12.5)
Generalized  lupus  erythematosus  35  (8.4)
Juvenile  idiopathic  arthritis 18  (4.3)
Scleroderma  7  (1.7)
Time of  use  (months),  mean  ±  SD  14.73  ±  13.43
(interval:
2-0.96)
Number of  relevant  comorbidities
No  comorbidities  183  (43.9)
1 comorbidity  179  (42.9)
2 comorbidities  39  (9.4)
3 or  more  16  (3.9)
History of  peptic  ulcer
Complicated  3  (0.7)
Uncomplicated  6  (1.4)
Type of  treatment
High  doses  of  NSAID  53  (12.7)
NSAID +  antiaggregants  (ASA)  26  (6.2)
NSAID +  steroids  130  (31.2)
NSAID  +  oral  anticoagulants  5  (1.2)
Table  2  Type  of  NSAID  used  (n  =  417).
Type  of  NSAID  n  (%)
Indomethacin  200  (48)
Diclofenac  95  (22.8)
Ibuprofen  31  (7.4)
Meloxicam  28  (6.7)
Naproxen  26  (6.2)
Piroxicam  9  (2.2)
Celecoxib  8  (1.9)
Ketorolac  7  (1.7)
Nimesulide  6  (1.4)
Others 7  (1.7)
Table  3  Presence  of  gastrointestinal  risk  factorsa (n  =  417
[%]).
Without  factors  206  (48.9%)Are  the  clinical  guideline  recommendations  on  gastroprotec
in  chronic  NSAID  users,  and  therefore  in  this  work  we
decided  to  evaluate  whether:  1)  gastroprotection  was  car-
ried  out,  and  2)  if  the  clinical  guideline  criteria  were
applied.
Materials and methods
A  descriptive,  cross-sectional  study  was  conducted  that
reviewed  the  case  records  of  the  patients  seen  as
outpatients  at  the  Rheumatology  Department  of  the  Insti-
tuto  Nacional  de  Ciencias  Médicas  y  Nutrición  ‘‘Salvador
Zubirán’’,  Mexico  City,  within  the  time  frame  of  February
1,  2015  to  May  30,  2015.  Patients  that  were  chronic  NSAID
users  were  chosen  for  the  analysis.  Those  patients  that  had
already  presented  with  NSAID-associated  complications  and
those  in  whom  it  was  not  possible  to  complete  the  required
data  were  excluded  from  the  study.  The  demographic  data,
comorbidities,  risk  factors  for  adverse  effects  related  to
NSAID  use,  and  the  gastroprotection  measures  employed
were  recorded.
Chronic  NSAID  use  was  deﬁned  as  the  ingestion  of  the
medication  for  3  or  more  days  per  week  for  more  than
a  month.  The  prescribed  NSAID  dose  above  that  which
is  recommended  was  considered  high  dose.  The  guideline
recommendations  published  by  the  American  College  of  Gas-
troenterology  (2009)  and  ratiﬁed  in  the  Clinical  Guidelines
for  the  Diagnosis  and  Treatment  of  Peptic  Ulcer  Disease  pub-
lished  by  the  Asociación  Mexicana  de  Gastroenterología11--13
were  used  to  evaluate  the  implementation  of  gastropro-
tection  measures.  The  primary  outcome  measure  was  to
evaluate  the  prevalence  rate  of  the  use  of  gastroprotection
measures  according  to  the  stratiﬁcation  of  gastrointestinal
and  cardiovascular  risk.
The  results  were  expressed  in  percentages  (%)  and
means.
Results
A  total  of  4,500  case  records  were  reviewed  during  the
study  period  and  417  patients  that  were  chronic  NSAID  users
were  identiﬁed.  Three  hundred  forty-seven  (83.2%)  of  those
patients  were  women  and  70  (16.8%)  were  men.  The  mean
age  of  the  total  group  was  48.12  ±  14.2  years.  Table  1
shows  the  patient  characteristics.  Indomethacin  was  the
most  widely  used  NSAID  (Table  2).  Tables  3  and  4  show  the
stratiﬁcation  of  the  patients  according  to  the  number  of  risk
factors  and  the  group  to  which  they  belonged.
PPIs  were  prescribed  in  65  (31%)  of  the  211  patients  that
had  one  or  2  risk  factors  (moderate)  and  in  31  (15%)  that  had
none.  Two  of  the  7  patients  classiﬁed  as  high-risk  received
PPIs.  Gastrointestinal  prophylaxis  was  indicated  in  18  (38%)
of  the  48  patients  65  years  of  age  or  older,  in  9  (35%)  of  the
26  patients  with  concomitant  aspirin  use,  and  in  44  (34%)  of
the  130  patients  that  also  received  steroids.  Table  5  shows
the  medication  used  for  gastroprotection.  Proximal  gastroin-
testinal  endoscopy  was  performed  in  65  cases  (15.3%)  that
was  indicated  for  anemia  or  a  history  of  gastrointestinal
bleeding  and  was  reported  as  normal  in  20  of  the  patients.
Twenty-six  had  erosive  gastropathy  and  the  rest  of  the  ﬁnd-
ings  are  summarized  in  Table  6.
1  factor  156  (37.9%)
2 factors  51  (12.2%)
3 or  more  4  (1%)
a History of peptic ulcer, age > 65 years, high doses of NSAID,
aspirin use, steroid use, anticoagulant use.
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Table  4  Stratiﬁcation  according  to  gastrointestinal  risk  for
adverse  effects  from  NSAIDs.
Risk  n  (%)
Low  206  (49.4)
Moderate  204  (48.9)
High 7  (1.7)
Table  5  Type  of  PPI  used.
PPI  n  =  96  (%)
Omeprazole  20  mg 86  (89.5)
Pantoprazole  40  mg 5  (5.2)
Esomeprazole  40  mg  3  (3.1)
Dexlansoprazole  30  mg  2  (2.2)
Table  6  Endoscopic  ﬁndings  in  65  patients  using  NSAIDs.
Findings  n  (%)  PPI
Erosive  gastropathy  26  (40)  14
Normal 20  (31)  3
Atrophic  gastropathy  6  (9)  0
Duodenal  erosions  5  (8)  3
Duodenal  ulcer  4  (6)  2
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Right  to  privacy  and  informed  consent.  The  authors  have
obtained  the  informed  consent  of  the  patients  and/or  sub-Others 4  (6)  –
iscussion
hronic  NSAID  use  in  high-risk  patients  has  been  related  to
evere  complications.  Around  25%  of  users  may  develop  pep-
ic  ulcer  disease  and  2  to  4%,  bleeding  and  perforation.1
vidence  shows  that  the  application  of  prophylactic  meas-
res  considerably  reduces  these  eventualities  that  cause
ver  100,000  hospitalizations  per  year  in  the  United  States
nd  7,000  to  10,000  annual  deaths,  mainly  in  high-risk
atients.2,3,11,12
The  group  of  patients  included  in  the  present  study
howed  a  high  prevalence  of  risk  factors  for  gastrointesti-
al  adverse  effects.  All  were  chronic  anti-inﬂammatory  drug
onsumers,  a  signiﬁcant  percentage  were  older  than  65
ears  of  age,  and  at  least  one  third  had  concomitant  use
f  steroids  or  aspirin,  thus  representing  a  population  requir-
ng  gastroprotection.  In  addition,  indomethacin,  one  of  the
ost  ulcerogenic  NSAIDS,  was  the  most  widely  used.
It  is  not  surprising  that  half  of  these  patients  required
astroprotection,  but  only  65  of  the  211  (31%)  received  it.
nfortunately,  the  discouraging  ﬁndings  of  this  study  are  not
xclusive  to  our  environment.  Morini  et  al.  analyzed  869
atients  that  were  chronic  NSAID  users  of  which  68.2%  (593)
ad  gastroprotection,  but  only  34.4%  in  an  adequate  man-
er.  Underuse  was  observed  in  30.6%  of  the  patients  above
5  years  of  age.14 Sturkenboom  et  al.,  with  a  greater  num-
er  of  evaluated  patients  (n  =  69,648),  reported  that  of  the
,811  patients  with  2  or  more  risk  factors,  no  measure  of
astrointestinal  prophylaxis  was  taken  in  81.2%  of  them.15n  the  other  hand,  PPI  overuse  as  a  prophylactic  measure
as  been  shown  in  several  studies.  We  found  such  overuse
j
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n  15%  of  the  cases,  a  lower  ﬁgure  than  is  reported  in  other
nalyses.15
Different  studies  have  analyzed  the  inﬂuence  that  H.
ylori  infection  has  on  persons  with  chronic  NSAID  use.16,17
ts  importance  is  such  that  all  the  clinical  guidelines,
ncluding  those  in  Mexico,  recommend  searching  for  it  and
liminating  it  in  patients  that  require  chronic  NSAID  or  PPI
se.18 Patients  with  rheumatoid  diseases,  such  as  those  in
he  present  study,  require  both  medications  and  therefore
re  patients  in  whom  H.  pylori  must  be  ruled  out.  This  was
one  in  only  53  of  the  cases,  corresponding  to  a  mere  13%  of
he  study  population.  It  was  more  striking  to  ﬁnd  that  only
6%,  that  is  to  say,  9  of  the  53  subjects,  had  a  positive  test,
hich  was  a gastric  biopsy  analyzed  by  a  pathologist.  This  is
 relevant  fact  in  a country  where  H.  pylori  infection  affects
 large  percentage  of  adults,  and  even  more  so,  considering
he  high  number  of  patients  65  years  of  age  or  older.  We
ave  no  satisfactory  explanation  for  this  ﬁnding.
As  can  be  seen  from  the  present  analysis,  primary  pro-
hylaxis  for  lesions  attributable  to  chronic  NSAID  use  was
ub-optimal.  It  was  not  indicated  in  the  majority  of  cases  and
as  overused  in  others.  The  intentional  search  for  an  addi-
ive  damage  factor,  such  as  H.  pylori  infection,  was  low,  but
he  infection  detected  in  a  small  group  of  patients  was  sur-
risingly  lower  than  that  reported  in  the  general  population.
he  factors  that  were  most  associated  with  PPI  subuse  in  this
roup  of  patients  were  the  high  doses  of  NSAIDs,  the  con-
omitant  use  of  steroids  or  aspirin,  and  age  above  65  years.
ven  though  there  were  no  severe  complications  in  any  of
he  cases,  endoscopic  study  that  had  to  be  performed  on
5  patients  showed  ulcerative  lesions  in  an  important  num-
er  of  them  (70%).  It  is  possible  that  the  lesions  attributable
o  NSAID-induced  gastropathy  go  unperceived,  in  addition  to
he  fact  that  many  patients  present  with  asymptomatic  pep-
ic  ulcer  due  to  the  analgesic  effect  of  the  NSAIDs  and  then
ave  the  complication  of  bleeding  with  no  prior  symptoms.
In  conclusion,  prophylaxis  with  PPIs  in  chronic  NSAID  users
as  inadequately  employed.  It  was  not  prescribed  in  the
ajority  of  cases  (69.2%)  and  it  was  used  unjustiﬁably  in
thers  (15%).  There  were  very  few  intentional  searches  for
.  pylori  infection,  a  factor  with  a  synergic  capacity  for
astric  involvement.  While  the  conﬁrmation  of  these  results
t  other  sites  is  pending,  the  different  medical  groups  and
ealthcare  providers  should  establish  measures  that  guar-
ntee  the  application  of  the  clinical  guidelines  that  exist  to
mprove  the  quality  of  medical  attention  standards.
thical responsibilities
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